Publications

• Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
  Eur J Cancer Volume: 221 Page(s): 115397
  05/15/2025 Authors: Bedard PL; Jhaveri KL; Accordino MK; Cervantes PA; Gambardella V; Hamilton E; Italiano PA; Kalinsky PK; Krop PIE; Oliveira M
• MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.
  Nat Commun Volume: 16 Page(s): 3552
  04/15/2025 Authors: Chi JJ; Xie P; Cheng MH; Zhu Y; Cui X; Watson J; Zeng L; Uddin A; Nguyen H; Li L
• Current controversies in the use of Oncotype DX in early breast cancer.
  Cancer Treat Rev Volume: 135 Page(s): 102887
  04/01/2025 Authors: Berton Giachetti PPM; Carnevale Schianca A; Trapani D; Marra A; Toss A; Marchi C; Dieci MV; Gentilini OD; Criscitiello C; Kalinsky K
• Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
  J Clin Oncol Volume: 43 Page(s): 1101 - 1112
  03/20/2025 Authors: Kalinsky K; Bianchini G; Hamilton E; Graff SL; Park KH; Jeselsohn R; Demirci U; Martin M; Layman RM; Hurvitz SA
• Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
  J Clin Oncol Volume: 43 Page(s): 919 - 928
  03/10/2025 Authors: Pusztai L; Hoag JR; Albain KS; Barlow WE; Stemmer SM; Meisner A; Hortobagyi GN; Shak S; Rae JM; Baehner R
• Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.
  JCO Precis Oncol Volume: 9 Page(s): e2400614
  03/01/2025 Authors: McCourt CK; Gross J; Kalinsky K; Guan P; McShane LM; Wang V; O'Dwyer PJ; Lahey MT; Maican C; Bu X
• Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.
  Sci Rep Volume: 15 Page(s): 7220
  02/28/2025 Authors: Jones V; Yin HH; Yuan Y-C; Wang Y; Li SM; Aljaber D; Sanchez A; Quinones C; Schmolze D; Yuan Y
• Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
  Eur J Cancer Volume: 217 Page(s): 115225
  02/25/2025 Authors: Hart LL; Im S-A; Tolaney SM; Campone M; Pluard T; Sousa B; Freyer G; Decker T; Kalinsky K; Sopher G
• Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.
  J Clin Oncol Volume: 43 Page(s): 487 - 491
  02/10/2025 Authors: Thomas A; Mayer EL; DeMichele A; Harbeck N; Curigliano G; Ignatiadis M; Adam V; Zhou Y; Brown TP; Gilham L
• "Nailing down" risk and improving outcomes in early-stage breast cancer.
  J Natl Cancer Inst Volume: 117 Page(s): 205 - 208
  02/01/2025 Authors: Graff SL; Tinianov S; Kalinsky K
• Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer.
  JCO Oncol Pract Volume: 21 Page(s): 199 - 208
  02/01/2025 Authors: Sathe C; Raghunathan R; Ulene S; McAuley F; Bhatt KA; McGuinness JE; Trivedi MS; Vasan N; Kalinsky KM; Crew KD
• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
  J Clin Oncol Volume: 43 Page(s): 285 - 296
  01/20/2025 Authors: Bardia A; Jhaveri K; Im S-A; Pernas S; De Laurentiis M; Wang S; Martnez Jaez N; Borges G; Cescon DW; Hattori M
• Top advances of the year: Breast cancer.
  Cancer Volume: 131 Page(s): e35669
  01/01/2025 Authors: Farley CR; Sakach E; Ridge N; Sacks R; Kalinsky K
• Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
  J Natl Cancer Inst
  12/05/2024 Authors: Abdou Y; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL
• Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
  Nat Med Volume: 30 Page(s): 3728 - 3736
  12/01/2024 Authors: Khoury K; Meisel JL; Yau C; Rugo HS; Nanda R; Davidian M; Tsiatis B; Chien AJ; Wallace AM; Arora M
• Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
  Nat Med Volume: 30 Page(s): 3737 - 3747
  12/01/2024 Authors: Shatsky RA; Trivedi MS; Yau C; Nanda R; Rugo HS; Davidian M; Tsiatis B; Wallace AM; Chien AJ; Stringer-Reasor E
• Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
  J Clin Oncol Volume: 42 Page(s): 3947 - 3956
  11/20/2024 Authors: Jhaveri KL; Accordino MK; Bedard PL; Cervantes A; Gambardella V; Hamilton E; Italiano A; Kalinsky K; Krop IE; Oliveira M
• Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
  Breast Cancer Res Treat Volume: 208 Page(s): 203 - 214
  11/01/2024 Authors: Kalinsky K; Spring L; Yam C; Bhave MA; Ntalla I; Lai C; Sjekloca N; Stwalley B; Stokes M; Taylor A
• Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
  Eur J Nucl Med Mol Imaging Volume: 51 Page(s): 4073 - 4082
  11/01/2024 Authors: Mushtaq A; Lawal IO; Muzahir S; Friend SC; Bhave M; Meisel JL; Torres MA; Styblo TM; Graham CL; Kalinsky K
• Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
  N Engl J Med Volume: 391 Page(s): 1584 - 1596
  10/31/2024 Authors: Turner NC; Im S-A; Saura C; Juric D; Loibl S; Kalinsky K; Schmid P; Loi S; Sunpaweravong P; Musolino A
• Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
  Breast Cancer Res Treat Volume: 207 Page(s): 599 - 609
  10/01/2024 Authors: Bhave MA; Quintanilha JCF; Tukachinsky H; Li G; Scott T; Ross JS; Pasquina L; Huang RSP; McArthur H; Levy MA
• Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
  Breast Cancer Res Treat Volume: 207 Page(s): 611 - 614
  10/01/2024 Authors: Bhave MA; Quintanilha JCF; Tukachinsky H; Li G; Scott T; Ross JS; Pasquina L; Huang RSP; McArthur H; Levy MA
• Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
  Nat Rev Clin Oncol Volume: 21 Page(s): 743 - 761
  10/01/2024 Authors: Lloyd MR; Jhaveri K; Kalinsky K; Bardia A; Wander SA
• Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs.
  Adv Sci (Weinh) Volume: 11 Page(s): e2400757
  10/01/2024 Authors: Zeng L; Zhu Y; Cui X; Chi J; Uddin A; Zhou Z; Song X; Dai M; Cristofanilli M; Kalinsky K
• FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.
  EMBO Mol Med Volume: 16 Page(s): 1957 - 1980
  08/01/2024 Authors: Tai Y; Chow A; Han S; Coker C; Ma W; Gu Y; Estrada Navarro V; Kandpal M; Hibshoosh H; Kalinsky K
• Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ Breast Cancer Volume: 10 Page(s): 55
  07/09/2024 Authors: Hurvitz SA; Bardia A; Punie K; Kalinsky K; Carey LA; Rugo HS; Diras V; Phan S; Delaney R; Zhu Y
• The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life.
  JCO Oncol Pract Volume: 20 Page(s): 972 - 983
  07/01/2024 Authors: Loeser A; Kim JS; Peppercorn J; Burkard ME; Niemierko A; Juric D; Kalinsky K; Rugo H; Glenn L; Hodgdon C
• Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ Breast Cancer Volume: 10 Page(s): 41
  06/06/2024 Authors: Rugo HS; Tolaney SM; Loirat D; Punie K; Bardia A; Hurvitz SA; O'Shaughnessy J; Corts J; Diras V; Carey LA
• Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
  J Clin Oncol Volume: 42 Page(s): 1738 - 1744
  05/20/2024 Authors: Bardia A; Rugo HS; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Kalinsky K; Corts J; Shaughnessy JO
• Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ Breast Cancer Volume: 10 Page(s): 33
  04/25/2024 Authors: Hurvitz SA; Bardia A; Punie K; Kalinsky K; Carey LA; Rugo HS; Diras V; Phan S; Delaney R; Zhu Y
• Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
  J Clin Invest Volume: 134
  03/26/2024 Authors: Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y
• TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
  Future Oncol Volume: 20 Page(s): 423 - 436
  03/01/2024 Authors: Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im S-A; Nowecki Z; Sohn J
• Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.
  Breast Cancer Res Treat Volume: 204 Page(s): 49 - 59
  02/01/2024 Authors: Accordino MK; Lee S; Leu CS; Levin B; Trivedi MS; Crew KD; Kalinsky K; Raghunathan R; Faheem K; Harden E
• The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
  Nat Commun Volume: 15 Page(s): 466
  01/11/2024 Authors: Lewis GD; Li G; Guo J; Yu S-F; Fields CT; Lee G; Zhang D; Dragovich PS; Pillow T; Wei B
• TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
  Ther Adv Med Oncol Volume: 16 Page(s): 17588359241248336
  01/01/2024 Authors: Bardia A; Pusztai L; Albain K; Ciruelos EM; Im S-A; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L
• Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes.
  Ann Oncol Volume: 35 Page(s): 7 - 9
  01/01/2024 Authors: Thomas A; Shatsky R; Kalinsky K
• CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
  Curr Treat Options Oncol Volume: 24 Page(s): 1103 - 1119
  09/01/2023 Authors: Sakach E; Keskinkilic M; Wood S; Canning M; Kalinsky K
• Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
  J Clin Oncol Volume: 41 Page(s): 4004 - 4013
  08/20/2023 Authors: Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A
• Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
  JAMA Oncol Volume: 9 Page(s): 1083 - 1089
  08/01/2023 Authors: Jagsi R; Barlow WE; Woodward WA; Connolly E; Mahtani R; Shumway D; Speers C; Stecklein SR; Zeidan Y; Zhang H
• Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
  Breast Cancer Res Treat Volume: 201 Page(s): 105 - 115
  08/01/2023 Authors: Kruse M; Smyth EN; Bowman L; Gautam S; Guimaraes CM; Nisbett AR; Fisher MD; Cui ZL; Sheffield KM; Kalinsky K
• A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
  Cancer Discov Volume: 13 Page(s): 1386 - 1407
  06/02/2023 Authors: Mundi PS; Dela Cruz FS; Grunn A; Diolaiti D; Mauguen A; Rainey AR; Guillan K; Siddiquee A; You D; Realubit R
• Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor.
  Nat Cancer Volume: 4 Page(s): 809 - 811
  06/01/2023 Authors: Silva J; Yu J; Kalinsky K
• Advances in SERDs and other novel endocrine therapies.
  Clin Adv Hematol Oncol Volume: 21 Page(s): 294 - 296
  06/01/2023 Authors: Kalinsky K
• A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
  JCO Precis Oncol Volume: 7 Page(s): e2200532
  05/01/2023 Authors: Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A
• Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.
  ESMO Open Volume: 8 Page(s): 100884
  04/01/2023 Authors: Hecht JR; Raman SS; Chan A; Kalinsky K; Baurain J-F; Jimenez MM; Garcia MM; Berger MD; Lauer UM; Khattak A
• A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment.
  Clin Nucl Med Volume: 48 Page(s): e202 - e203
  04/01/2023 Authors: Adediran OA; Lawal IO; Muzahir S; Bhave MA; Friend S; Fielder B; Meisel J; Torres MA; Styblo TM; Graham C
• Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
  Future Oncol Volume: 19 Page(s): 559 - 573
  03/01/2023 Authors: Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL
• Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
  Volume: 4 Page(s): 257 - 275
  02/01/2023 Authors: Zeleke TZ; Pan Q; Chiuzan C; Onishi M; Li Y; Tan H; Alvarez MJ; Honan E; Yang M; Chia PL
• Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
  Sci Adv Volume: 9 Page(s): eadd6626
  01/06/2023 Authors: Fu Z; Chen S; Zhu Y; Zhang D; Xie P; Jiao Q; Chi J; Xu S; Xue Y; Lu X
• Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center.
  Clin Breast Cancer Volume: 23 Page(s): 38 - 44
  01/01/2023 Authors: Aldrich J; Ekpo P; Rupji M; Switchenko JM; Torres MA; Kalinsky K; Bhave MA
• Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
  Eur J Cancer Volume: 178 Page(s): 23 - 33
  01/01/2023 Authors: Loibl S; Loirat D; Tolaney SM; Punie K; Oliveira M; Rugo HS; Bardia A; Hurvitz SA; Brufsky AM; Kalinsky K
• A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.
  Clin Nucl Med Volume: 48 Page(s): e26 - e27
  01/01/2023 Authors: Lawal IO; Adediran OA; Muzahir S; Friend S; Bhave MA; Meisel J; Torres MA; Styblo TM; Graham C; Holbrook A
• The role of immune checkpoint inhibition in triple negative breast cancer.
  Expert Rev Anticancer Ther Volume: 23 Page(s): 1095 - 1106
  01/01/2023 Authors: Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
• Discusses the Past, Present, and Future of Breast Cancer Research
  ONCOLOGY-NEW YORK Volume: 37
  01/01/2023 Authors: Kalinsky K
• Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
  Breast Cancer Res Treat Volume: 196 Page(s): 549 - 563
  12/01/2022 Authors: Loeser AL; Gao L; Bardia A; Burkard ME; Kalinsky KM; Peppercorn J; Rugo HS; Carlson M; Cowden J; Glenn L
• Trop-2 as a Therapeutic Target in Breast Cancer.
  Cancers (Basel) Volume: 14
  11/30/2022 Authors: Sakach E; Sacks R; Kalinsky K
• Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
  NPJ Breast Cancer Volume: 8 Page(s): 119
  11/07/2022 Authors: Qing T; Karn T; Rozenblit M; Foldi J; Marczyk M; Shan NL; Blenman K; Holtrich U; Kalinsky K; Meric-Bernstam F
• Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).
  Cardiovasc Intervent Radiol Volume: 45 Page(s): 1725 - 1734
  11/01/2022 Authors: Wu R; Gogineni K; Meisel J; Szabo S; Thirunavu M; Friend S; Bercu Z; Sethi I; Natarajan N; Switchenko J
• Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
  J Clin Oncol Volume: 40 Page(s): 3205 - 3221
  09/20/2022 Authors: Henry NL; Somerfield MR; Dayao Z; Elias A; Kalinsky K; McShane LM; Moy B; Park BH; Shanahan KM; Sharma P
• Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2-) breast cancer: TROPION-Breast01
  Volume: 33 Page(s): S663 - S663
  09/13/2022 Authors: Bardia A; Kalinsky K; Tsurutani J; Hamilton EP; Johnston S; Sohn J; Park KH; Park YH; Im S-A; Lee KS
• Efficacy of Sacituzumab Govitecan (SG) in Patients with metastatic triple negative Breast Cancer (mTNBC) by HER2 Immunohistochemistry (IHC) Status: Results from the Phase 3 ASCENT Study
  Volume: 45 Page(s): 104 - 105
  09/01/2022 Authors: Hegewisch-Becker S; Hurvitz SA; Bardia A; Punie K; Kalinsky K; Cortes J; O'Shaughnessy J; Carey LA; Rugo HS; Yoon OK
• Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A.
  JCO Oncol Pract Volume: 18 Page(s): 646 - 648
  09/01/2022 Authors: Raab R; Ismaila N; Andre F; Stearns V; Kalinsky K
• Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
  Breast Cancer Res Treat Volume: 195 Page(s): 127 - 139
  09/01/2022 Authors: O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R
• Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ Breast Cancer Volume: 8 Page(s): 98
  08/29/2022 Authors: Rugo HS; Tolaney SM; Loirat D; Punie K; Bardia A; Hurvitz SA; O'Shaughnessy J; Corts J; Diras V; Carey LA
• Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
  J Clin Oncol Volume: 40 Page(s): 2395 - 2397
  08/01/2022 Authors: Cescon DW; Kalinsky K; DeMichele AM
• Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
  Clin Breast Cancer Volume: 22 Page(s): 538 - 546
  08/01/2022 Authors: Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu C-S
• Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.
  Breast Cancer Res Treat Volume: 194 Page(s): 35 - 47
  07/01/2022 Authors: McGuinness JE; Ro V; Mutasa S; Pan S; Hu J; Trivedi MS; Accordino MK; Kalinsky K; Hershman DL; Ha RS
• Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
  Ann Oncol Volume: 33 Page(s): 702 - 712
  07/01/2022 Authors: Trapani D; Franzoi MA; Burstein HJ; Carey LA; Delaloge S; Harbeck N; Hayes DF; Kalinsky K; Pusztai L; Regan MM
• Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
  NPJ Breast Cancer Volume: 8 Page(s): 72
  06/09/2022 Authors: Carey LA; Loirat D; Punie K; Bardia A; Diras V; Dalenc F; Diamond JR; Fontaine C; Wang G; Rugo HS
• Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
  J Clin Oncol Volume: 40 Page(s): 1816 - 1837
  06/01/2022 Authors: Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM
• Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide Assay.
  Clin Breast Cancer Volume: 22 Page(s): e457 - e462
  06/01/2022 Authors: Wooster M; McGuinness JE; Fenn KM; Singh VM; Franks LE; Lee S; Cieremans D; Lassman AB; Hershman DL; Crew KD
• Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greatertrust": [Annals of Oncology 32 (2021) 1077-1082].
  Ann Oncol Volume: 33 Page(s): 668
  06/01/2022 Authors: Piccart MJ; Kalinsky K; Gray R; Barlow WE; Poncet C; Cardoso F; Winer E; Sparano J
• Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer.
  JCO Oncol Pract Volume: 18 Page(s): 247 - 251
  04/01/2022 Authors: Gogineni K; Kalinsky K
• Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
  Breast Cancer Res Treat Volume: 192 Page(s): 509 - 516
  04/01/2022 Authors: Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
• Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
  Ther Adv Med Oncol Volume: 14 Page(s): 17588359221084769
  01/01/2022 Authors: Taylor C; Meisel J; Kalinsky K
• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
  N Engl J Med Volume: 385 Page(s): 2336 - 2347
  12/16/2021 Authors: Kalinsky K; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL
• Error in the Abstract.
  JAMA Oncol Volume: 7 Page(s): 1729
  11/01/2021
• Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
  Clin Breast Cancer Volume: 21 Page(s): 383 - 390
  10/01/2021 Authors: Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M; Breast Cancer Therapy Expert Group (BCTEG)
• Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
  Volume: 44 Page(s): 133 - 133
  09/01/2021 Authors: Hegewisch-Becker S; Loirat DL; Punie K; Bardia A; Dieras V; Dalenc F; Diamond JR; Fontaine C; Wang G; Rugo HS
• Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
  Ann Oncol Volume: 32 Page(s): 1077 - 1082
  09/01/2021 Authors: Piccart MJ; Kalinsky K; Gray R; Barlow WE; Poncet C; Cardoso F; Winer E; Sparano J
• Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
  Volume: 32 Page(s): 1148 - 1156
  09/01/2021 Authors: Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
  J Immunother Cancer Volume: 9
  08/01/2021 Authors: Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R
• Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
  Breast Cancer Res Treat Volume: 189 Page(s): 1 - 13
  08/01/2021 Authors: Kearney MR; McGuinness JE; Kalinsky K
• Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
  Breast Cancer Res Treat Volume: 189 Page(s): 297 - 304
  08/01/2021 Authors: McGuinness JE; Altoe ML; Marone A; Franks LE; Lee SM; Kim HK; Tejada M; Trivedi MS; Accordino MK; Crew KD
• Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
  Breast Cancer Res Treat Volume: 189 Page(s): 177 - 185
  08/01/2021 Authors: Kearney M; Franks L; Lee S; Tiersten A; Makower DF; Cigler T; Mundi P; Chi D-C; Goel A; Klein P
• Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care.
  JCO Oncol Pract Volume: 17 Page(s): e1215 - e1224
  08/01/2021 Authors: Satish T; Raghunathan R; Prigoff JG; Wright JD; Hillyer GA; Trivedi MS; Kalinsky K; Crew KD; Hershman DL; Accordino MK
• Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
  Cancer Cell Volume: 39 Page(s): 989 - 998.e5
  07/12/2021 Authors: Pusztai L; Yau C; Wolf DM; Han HS; Du L; Wallace AM; String-Reasor E; Boughey JC; Chien AJ; Elias AD
• Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
  Expert Opin Biol Ther Volume: 21 Page(s): 903 - 913
  07/01/2021 Authors: McGuinness JE; Kalinsky K
• Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
  Breast Cancer Res Treat Volume: 188 Page(s): 427 - 432
  07/01/2021 Authors: Hopson MB; Lee S; Accordino M; Trivedi M; Maurer M; Crew KD; Hershman DL; Kalinsky K
• Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.
  Clin Breast Cancer Volume: 21 Page(s): e150 - e153
  06/01/2021 Authors: Bose S; Kalinsky K
• Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy.
  Nat Cancer Volume: 2 Page(s): 658 - 671
  06/01/2021 Authors: Griffiths JI; Chen J; Cosgrove PA; O'Dea A; Sharma P; Ma C; Trivedi M; Kalinsky K; Wisinski KB; O'Regan R
• Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
  Clin Cancer Res Volume: 27 Page(s): 3061 - 3068
  06/01/2021 Authors: Tolaney SM; Kalinsky K; Kaklamani VG; D'Adamo DR; Aktan G; Tsai ML; O'Regan RM; Kaufman PA; Wilks ST; Andreopoulou E
• Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
  Ann Oncol Volume: 32 Page(s): 746 - 756
  06/01/2021 Authors: Bardia A; Messersmith WA; Kio EA; Berlin JD; Vahdat L; Masters GA; Moroose R; Santin AD; Kalinsky K; Picozzi V
• Effect of Neoadjuvant Letrozole and Ribociclib on Nodal Pathologic Response in HR+/Her2-Breast Cancer (FELINE Trial)
  Volume: 28 Page(s): S247 - S248
  05/01/2021 Authors: Abbassi-Rahbar S; Khan QJ; Fan F; Gloyeske NC; Larson KE; Amin AL; Balanoff CR; Kilgore LJ; Sharma P; O'Dea AP
• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
  N Engl J Med Volume: 384 Page(s): 1529 - 1541
  04/22/2021 Authors: Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB
• Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes.
  Clin Cancer Res Volume: 27 Page(s): 1949 - 1957
  04/01/2021 Authors: Altoe ML; Kalinsky K; Marone A; Kim HK; Guo H; Hibshoosh H; Tejada M; Crew KD; Accordino MK; Trivedi MS
• Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
  J Natl Compr Canc Netw Page(s): 1 - 8
  03/24/2021 Authors: Wander SA; Han HS; Zangardi ML; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A
• When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management.
  Am Soc Clin Oncol Educ Book Volume: 41 Page(s): 1 - 11
  03/01/2021 Authors: Obeng-Gyasi S; Coles CE; Jones J; Sacks R; Lightowlers S; Bliss JM; Brunt AM; Haviland JS; Kirby AM; Kalinsky K
• Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
  JAMA Oncol Volume: 7 Page(s): 271 - 278
  02/01/2021 Authors: Kalinsky K; Hong F; McCourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; McShane LM; Li S; Gray RJ
• Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
  Breast Cancer Res Volume: 23 Page(s): 16
  01/31/2021 Authors: Altoe ML; Kalinsky K; Marone A; Kim HK; Guo H; Hibshoosh H; Tejada M; Crew KD; Accordino MK; Trivedi MS
• On the Road to Precision: Understanding the Biology Driving Genomic Assays.
  J Clin Oncol Volume: 39 Page(s): 100 - 102
  01/10/2021 Authors: Kalinsky K; Thomas A; Cescon DW
• Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches.
  Front Oncol Volume: 11 Page(s): 667397
  01/01/2021 Authors: Cescon DW; Kalinsky K; Parsons HA; Smith KL; Spears PA; Thomas A; Zhao F; DeMichele A
• Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
  Front Oncol Volume: 11 Page(s): 810023
  01/01/2021 Authors: Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T
• Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin.
  Cancer Invest Volume: 39 Page(s): 466 - 472
  01/01/2021 Authors: Marks DK; Kucharczyk J; Kim P; Chyong DI; Gartrell RD; Lu Y; Hibshoosh H; Guo H; Evans TRJ; Lopez J
• Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
  Ann Oncol Volume: 31 Page(s): 1709 - 1718
  12/01/2020 Authors: Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM
• Preoperative Pembrolizumab Treatment Changes Tils in Naive Stage I/IIA TNBC Patients Within a Window of Opportunity Trial
  Volume: 108 Page(s): E48 - E48
  11/01/2020 Authors: Wang Q; Vanguri R; Guo H; Boboila S; Kurc T; Le H; Abousamra S; Hou L; Samaras D; Gupta R
• The COVID-19 pandemic impact on breast cancer care delivery at an academic center in New York City.
  Volume: 38
  10/10/2020 Authors: Satish T; Raghunathan R; Prigoff J; Wright JD; Hillyer G; Trivedi MS; Kalinsky K; Crew KD; Hershman DL; Accordino MK
• Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City.
  Breast Cancer Res Treat Volume: 182 Page(s): 239 - 242
  07/01/2020 Authors: Kalinsky K; Accordino MK; Hosi K; Hawley JE; Trivedi MS; Crew KD; Hershman DL
• Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
  Clin Breast Cancer Volume: 20 Page(s): 183 - 193
  06/01/2020 Authors: Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M
• A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
  Clin Breast Cancer Volume: 20 Page(s): e251 - e260
  06/01/2020 Authors: Mahtani R; Holmes F-A; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M
• Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.
  Clin Breast Cancer Volume: 20 Page(s): e327 - e333
  06/01/2020 Authors: Hopson MB; Onishi M; Awad D; Buono D; Maurer M; Crew KD; Shane E; Hershman DL; Kalinsky K
• Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
  Clin Cancer Res Volume: 26 Page(s): 1781 - 1783
  04/15/2020 Authors: Blaes AH; Domingo-Musibay E; Kalinsky K
• Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events.
  Cancer Volume: 126 Page(s): 1541 - 1549
  04/01/2020 Authors: Hershman DL; Accordino MK; Shen S; Buono D; Crew KD; Kalinsky K; Trivedi MS; Hur C; Hu J; Unger JM
• Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC)
  Volume: 80
  02/01/2020 Authors: Kalinsky K; Chiuzan C; Onishi M; Trivedi MS; Accordino M; Zeleke T; Pan Q; Kelly S; Honan E; Wu R
• Early changes in diffuse optical tomography predicts pathologic complete response to neoadjuvant chemotherapy in triple-negative breast cancer
  Volume: 80
  02/01/2020 Authors: Altoe ML; Kalinsky K; Guo H; Hibshoosh H; Tejada M; Crew KD; Accordino MK; Trivedi MS; Marone A; Kim HK
• Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
  Volume: 80
  02/01/2020 Authors: Kalinsky K; Lee S; Tiersten A; Makower DF; Cigler T; Franks L; Mundi P; Chi D-C; Blumberg L; Sender N
• Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
  Clin Breast Cancer Volume: 20 Page(s): 80 - 86
  02/01/2020 Authors: Fenn K; Maurer M; Lee SM; Crew KD; Trivedi MS; Accordino MK; Hershman DL; Kalinsky K
• Preoperative pembrolizumab increases sTILs in treatment naive stage I/IIA TNBC patients in a window of opportunity trial
  Volume: 80
  02/01/2020 Authors: Vanguri R; Guo H; Boboila S; Kurc T; Le H; Abousamra S; Hou L; Samaras D; Gupta R; Saltz J
• Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer
  Volume: 80
  02/01/2020 Authors: Fenn KM; Marks DK; Vanguri R; Boboila S; Guo H; Hibshoosh H; Kalinsky K; Connolly E
• Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial
  Volume: 80
  02/01/2020 Authors: Helsten TL; Lo SS; Yau C; Kalinsky K; Elias AD; Wallace AM; Chien AJ; Lu J; Lang JE; Albain KS
• Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer
  Volume: 80
  02/01/2020 Authors: Hecht JR; Chan A; Baurain J-F; Martin M; Longo-Munoz F; Kalinsky K; Raman S; Liu C; Cha E; Chan E
• Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer.
  Front Oncol Volume: 10 Page(s): 968
  01/01/2020 Authors: Marks DK; Gartrell RD; El Asmar M; Boboila S; Hart T; Lu Y; Pan Q; Yu J; Hibshoosh H; Guo H
• Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
  JNCI Cancer Spectr Volume: 3 Page(s): pkz049
  12/01/2019 Authors: Dowling RJO; Sparano JA; Goodwin PJ; Bidard F-C; Cescon DW; Chandarlapaty S; Deasy JO; Dowsett M; Gray RJ; Henry NL
• Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
  JNCI Cancer Spectr Volume: 3 Page(s): pkz050
  12/01/2019 Authors: Dowling RJO; Kalinsky K; Hayes DF; Bidard F-C; Cescon DW; Chandarlapaty S; Deasy JO; Dowsett M; Gray RJ; Henry NL
• A standardized workflow to improve the consent process among patients initiating an oral anticancer drug.
  Volume: 37
  09/20/2019 Authors: Brown JS; Hershman DL; O'Neil D; Brafman L; Fuentes DA; Graafland L; Law C; Trivedi MS; Kalinsky K; Crew KD
• Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
  Drugs Today (Barc) Volume: 55 Page(s): 575 - 585
  09/01/2019 Authors: Fenn KM; Kalinsky K
• Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy.
  Biomed Opt Express Volume: 10 Page(s): 4305 - 4315
  08/01/2019 Authors: Altoe ML; Marone A; Kim HK; Kalinsky K; Hershman DL; Hielscher AH; Ha RS
• Current Landscape of Immunotherapy in Breast Cancer: A Review.
  JAMA Oncol Volume: 5 Page(s): 1205 - 1214
  08/01/2019 Authors: Adams S; Gatti-Mays ME; Kalinsky K; Korde LA; Sharon E; Amiri-Kordestani L; Bear H; McArthur HL; Frank E; Perlmutter J
• Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.
  N Engl J Med Volume: 380 Page(s): 2382
  06/13/2019 Authors: Bardia A; Mayer IA; Kalinsky K
• Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
  Future Oncol Volume: 15 Page(s): 1641 - 1653
  05/01/2019 Authors: O'Shaughnessy J; Kaklamani V; Kalinsky K
• Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
  N Engl J Med Volume: 380 Page(s): 741 - 751
  02/21/2019 Authors: Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG
• Akt inhibition associated with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC)
  Volume: 79
  02/01/2019 Authors: Marks DK; Gartrell RD; Pan Q; El Asmar M; Hart TD; Esancy CL; Lu Y; Yu J; Hibshoosh H; Connolly E
• PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072
  Volume: 79
  02/01/2019 Authors: Adams S; Hamilton E; Ott PA; Cho D; Kalinsky K; LoRusso P; Will M; Huels V; Benson B; Murias C
• Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as >= 3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
  Volume: 79
  02/01/2019 Authors: Kalinsky K; Isakoff SJ; Tolaney SM; Juric D; Mayer IA; Vahdat LT; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD
• Association between adherence to cardiovascular medications and cardiovascular events following a diagnosis of early stage breast cancer
  Volume: 79
  02/01/2019 Authors: Hershman DL; Accordino M; Shen S; Buono D; Crew KD; Kalinsky K; Trivedi MS; Unger JM; Wright JD
• A phase 1 study of erlotinib and metformin in advanced triple negative breast cancer
  Volume: 79
  02/01/2019 Authors: Fenn KM; Maurer MA; Lee SM; Crew KD; Trivedi MS; Accordino MK; Hershman DL; Kalinsky K
• Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
  J Magn Reson Imaging Volume: 49 Page(s): 518 - 524
  02/01/2019 Authors: Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
• Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
  Cancer Volume: 125 Page(s): 177 - 180
  01/15/2019 Authors: Kalinsky K; O'Regan RM
• If we build it they will come: targeting the immune response to breast cancer.
  NPJ Breast Cancer Volume: 5 Page(s): 37
  01/01/2019 Authors: Gatti-Mays ME; Balko JM; Gameiro SR; Bear HD; Prabhakaran S; Fukui J; Disis ML; Nanda R; Gulley JL; Kalinsky K
• Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
  NPJ Breast Cancer Volume: 5 Page(s): 34
  01/01/2019 Authors: Page DB; Bear H; Prabhakaran S; Gatti-Mays ME; Thomas A; Cobain E; McArthur H; Balko JM; Gameiro SR; Nanda R
• Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents.
  JCO Precis Oncol Volume: 2 Page(s): 1 - 6
  11/01/2018 Authors: Ingham MA; McGuinness JE; Kalinsky K; Schwartz GK
• AZD5363 in Patients (Pts) with Tumors with AKT Mutations: NCI-MATCH Subprotocol EAY131-Y, A Trial of the ECOG-ACRIN Cancer Research Group (EAY131-Y)
  Volume: 103 Page(s): E15 - E15
  11/01/2018 Authors: Kalinsky K; Hong F; Mccourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; Mcshane LM; Li S; Gray RJ
• Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
  Clin Transl Oncol Volume: 20 Page(s): 1474 - 1483
  11/01/2018 Authors: Kalinsky K; Sparano JA; Zhong X; Andreopoulou E; Taback B; Wiechmann L; Feldman SM; Ananthakrishnan P; Ahmad A; Cremers S
• Characterization of the Tumor Microenvironment (TME) with Quantitative Multiplex Immunofluorescence (qMIF) in a Cohort of Neoadjuvant Breast Cancer (BC) Patients: A Pilot Analysis
  Volume: 102 Page(s): E568 - E568
  11/01/2018 Authors: Chin C; Marks D; Hart TD; Saenger Y; Hibshoosh H; Kalinsky KM; Connolly EP
• Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
  Volume: 14 Page(s): 176 - 176
  11/01/2018 Authors: Tolaney SM; Kalinsky K; Kaklamani V; Savulsky C; Olivo M; Aktan G; Kaufman PA; Xing D; Almonte A; Misir S
• Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.
  Clin Transl Oncol Volume: 20 Page(s): 1280 - 1288
  10/01/2018 Authors: Liu YL; Chin C; Catanese B; Lee SM; Zhan S; Kalinsky K; Connolly EP
• A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
  Breast Cancer Res Treat Volume: 170 Page(s): 547 - 557
  08/01/2018 Authors: O'Shaughnessy J; DeMichele A; Ma CX; Richards P; Yardley DA; Wright GS; Kalinsky K; Steis R; Diab S; Kennealey G
• Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
  Breast Cancer Res Treat Volume: 171 Page(s): 11 - 20
  08/01/2018 Authors: Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M
• Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features.
  Clin Breast Cancer Volume: 18 Page(s): 229 - 233
  06/01/2018 Authors: Jadeja P; Ha R; Rohde C; Ascherman J; Grant R; Chin C; Connolly E; Kalinsky K; Feldman S; Taback B
• Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.
  Radiology Volume: 287 Page(s): 778 - 786
  06/01/2018 Authors: Gunther JE; Lim EA; Kim HK; Flexman M; Alto M; Campbell JA; Hibshoosh H; Crew KD; Kalinsky K; Hershman DL
• Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).
  Volume: 36
  05/20/2018 Authors: Marks DK; Gartrell RD; El Asmar M; Boboila S; Hart TD; Esancy CL; Lu Y; Hibshoosh H; Connolly E; Kalinsky K
• Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.
  Volume: 36
  05/20/2018 Authors: Kalinsky K; Onishi M; Yu J; Trivedi MS; Accordino MK; Crew KD
• Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations andPrognosis.
  Clin Breast Cancer Volume: 18 Page(s): 114 - 120
  04/01/2018 Authors: Liu YL; Choi C; Lee SM; Zhong X; Hibshoosh H; Kalinsky K; Connolly EP
• Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.
  Breast Cancer Res Treat Volume: 168 Page(s): 285
  02/01/2018 Authors: Liu YL; Connolly EP; Kalinsky K
• Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer
  Volume: 78
  02/01/2018 Authors: Kalinsky K; Harding JJ; DeMichele A; Infante JR; Gogineni K; Owonikoko TK; Isakoff S; Iliopoulos O; Patel MR; Munster P
• Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
  Volume: 78
  02/01/2018 Authors: Modi S; Pusztai L; Forero A; Mita M; Miller KD; Weise A; Krop I; Burris H; Kalinsky K; Tsai M
• Identifying risk factors and effect modifiers of trastuzumab-induced cardiotoxicity among multi-ethnic women with early-stage HER2-positive breast cancer Ariel
  Volume: 78
  02/01/2018 Authors: Yuan A; Topkara V; Hershman DL; Kalinsky K; Accordino MK; Trivedi MS; Yu A; Genkinger JM; Crew KD
• Cost-effectiveness analysis of intraoperative radiotherapy for ductal carcinoma in situ
  Volume: 78
  02/01/2018 Authors: Onishi M; Connolly EP; Wright JD; Vasan S; Gross T; Tsai W-Y; Chen L; Neugut AI; Accordino MK; Kalinsky K
• A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/ 6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)
  Volume: 78
  02/01/2018 Authors: Kalinsky K; Mundi PS; Chiuzan C; Accordino MK; Trivedi MS; Sparano JA; Oh SY; Tiersten A; O'Regan R; Esteva FJ
• A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer
  Volume: 78
  02/01/2018 Authors: Cascetta KP; Poulikakos P; Shapiro C; Fasano J; Bhardwaj A; Irie H; Goel A; Klein P; Adams S; Kalinsky K
• Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
  Breast Cancer Res Treat Volume: 167 Page(s): 277 - 288
  01/01/2018 Authors: Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
• Obesity and Survival in Women with Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy: Role of Tumor Subtype and Race
  Volume: 99 Page(s): E11 - E11
  10/01/2017 Authors: Liu Y; Catanese B; Saraf A; Lee SM; Zhang Y; Kalinsky KM; Connolly EP
• Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
  Clin Cancer Res Volume: 23 Page(s): 5711 - 5719
  10/01/2017 Authors: Gray JE; Heist RS; Starodub AN; Camidge DR; Kio EA; Masters GA; Purcell WT; Guarino MJ; Misleh J; Schneider CJ
• Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results
  Volume: 28
  09/01/2017 Authors: Tagawa ST; Faltas B; Lam E; Saylor P; Bardia A; Hajdenberg J; Morgans AK; Lim E; Kalinsky K; Petrylak DP
• Bevacizumab in breast cancer: a targeted therapy still in search of a target population.
  Semin Oncol Volume: 44 Page(s): 286 - 287
  08/01/2017 Authors: Marks DK; Kalinsky K
• A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
  Cancer Volume: 123 Page(s): 2688 - 2697
  07/15/2017 Authors: Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB
• Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
  Volume: 77
  07/01/2017 Authors: Gray JE; Heist RS; Starodub AN; Camidge DR; Kio E; Masters G; Purcell WT; Guarino MJ; Misleh J; Schneider CJ
• Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
  J Clin Oncol Volume: 35 Page(s): 2141 - 2148
  07/01/2017 Authors: Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M
• Differences in global toxicity burden among patients and care providers during initial chemotherapy for breast cancer.
  Volume: 35
  05/20/2017 Authors: Rowland JC; Hershman DL; Kalinsky K; Crew KD; Cheung YK; Lee SM
• Obesity and survival in the neoadjuvant breast cancer setting: Role of tumor subtype and race.
  Volume: 35
  05/20/2017 Authors: Liu Y; Catanese BP; Saraf A; Lee S; Zhang Y; Connolly E; Kalinsky K
• Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.
  Volume: 35
  05/20/2017 Authors: Liu Y; Catanese BP; Chin C; Lee S; Zhan S; Kalinsky K; Connolly E
• Characterization of the tumor immune microenvironment (TIM) with multiplex immunohistochemistry (mIHC) in patients with breast cancer following treatment with MK-2206.
  Volume: 35
  05/20/2017 Authors: Marks DK; Gartrell RD; El Asmar M; Hart T; Lu Y; Esancy C; Hibshoosh H; Connolly E; Kalinsky K; Saenger YM
• Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
  Breast Cancer Res Treat Volume: 162 Page(s): 533 - 540
  04/01/2017 Authors: Lim EA; Gunther JE; Kim HK; Flexman M; Hibshoosh H; Crew K; Taback B; Campbell J; Kalinsky K; Hielscher A
• The Oncologic Safety and Cosmetic Success of Nipple-Sparing Mastectomy After Neoadjuvant Chemotherapy
  Volume: 24 Page(s): S56 - S56
  02/01/2017 Authors: Jadeja P; Chin C; Cantanese B; Saraf A; Kalinsky K; Ha R; Connolly E; Chen-Seetoo M; Feldman S; Taback B
• A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation
  Volume: 77
  02/01/2017 Authors: O'Shaughnessy J; DeMichele A; Ma C; Richards P; Yardley DA; Wright G; Kalinsky K; Steis R; Di Ab S; Kennealey G
• Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
  Volume: 77
  02/01/2017 Authors: Bardia A; Diamond JR; Mayer IA; Isakoff SJ; Abramson V; Starodub AN; O'Shaughnessy J; Kalinsky K; Moroose R; Shah N
• Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
  Volume: 77
  02/01/2017 Authors: Mundi PS; Lee S; Chi D; Bhardwaj A; Makower D; Cigler T; Crew KD; Hershman DL; Califano A; Silva J
• Diffuse optical tomography can predict pathologic complete response in patients with HER2+or triple negative breast cancer undergoing neoadjuvant chemotherapy
  Volume: 77
  02/01/2017 Authors: Kalinsky K; Lee S; Zhong X; Lim EA; Gunther JE; Hibshoosh H; Kim HK; Accordino M; Crew K; Hielscher A
• Inhibition of HDAC6 as targeted therapy for breast cancers
  Volume: 77
  02/01/2017 Authors: Silva J; Kalinsky K; Quayle S; Yang M
• A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer
  Volume: 77
  02/01/2017 Authors: Mundi PS; Codruta C; Accordino MK; Sparano J; Andreopoulou E; Vadhat LT; Tiersten A; Esteva F; O'Regan R; Jain S
• Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
  Clin Transl Oncol Volume: 19 Page(s): 180 - 188
  02/01/2017 Authors: Kalinsky K; Zheng T; Hibshoosh H; Du X; Mundi P; Yang J; Refice S; Feldman SM; Taback B; Connolly E
• Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors.
  J Cancer Surviv Volume: 10 Page(s): 956 - 963
  12/01/2016 Authors: Greenlee H; Molmenti CLS; Crew KD; Awad D; Kalinsky K; Brafman L; Fuentes D; Shi Z; Tsai W-Y; Neugut AI
• Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The Cocinar Para Su Salud! Randomized Controlled Trial.
  Cancer Epidemiol Biomarkers Prev Volume: 25 Page(s): 1491 - 1502
  11/01/2016 Authors: Greenlee H; Ogden Gaffney A; Aycinena AC; Koch P; Contento I; Karmally W; Richardson JM; Shi Z; Lim E; Tsai W-Y
• AKT in cancer: new molecular insights and advances in drug development.
  Br J Clin Pharmacol Volume: 82 Page(s): 943 - 956
  10/01/2016 Authors: Mundi PS; Sachdev J; McCourt C; Kalinsky K
• A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
  Volume: 27
  10/01/2016 Authors: Beeram M; Tolaney SM; Beck JT; Dickler MN; Conlin AK; Dees C; Helsten TL; Conkling PR; Edenfield WJ; Richards DA
• Associations of Lymphovascular Invasion and Clinical Outcomes in Breast Cancer After Neoadjuvant Chemotherapy
  Volume: 96 Page(s): E15 - E15
  10/01/2016 Authors: Saraf A; Liu YL; Lee SM; Zhong X; Kalinsky K; Connolly EP
• An analysis of the relationship between metastases and cachexia in lung cancer patients.
  Cancer Med Volume: 5 Page(s): 2641 - 2648
  09/01/2016 Authors: Shiono M; Huang K; Downey RJ; Consul N; Villanueva N; Beck K; Fenn K; Dietz D; Yamaguchi T; Kato S
• Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
  Volume: 34
  06/20/2016 Authors: Bardia A; Diamond JR; Messersmith WA; Mayer IA; Isakoff SJ; Abramson VG; Berlin J; Starodub A; O'Shaughnessy J; Kalinsky K
• Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
  Breast Cancer Res Treat Volume: 157 Page(s): 555 - 564
  06/01/2016 Authors: Liu YL; Saraf A; Lee SM; Zhong X; Hibshoosh H; Kalinsky K; Connolly EP
• A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
  Volume: 34
  05/20/2016 Authors: Kalinsky K; Lee SJ; Rubin KM; Lawrence DP; Iafrate AJ; Borger DR; Margolin KA; Leitao MM; Koon HB; Tarhini AA
• Lymphovascular invasion and survival in breast cancer after neoadjuvant chemotherapy.
  Volume: 34
  05/20/2016 Authors: Liu Y; Saraf A; Lee SM; Zhong X; Kalinsky K; Connolly E
• Pleomorphic invasive lobular breast carcinoma: Prognosis and characteristics compared with classical invasive lobular breast carcinoma.
  Volume: 34
  05/20/2016 Authors: Choi CH; Liu Y; Kalinsky K; Connolly E
• Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132) in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).
  Volume: 34
  05/20/2016 Authors: Starodub A; Camidge DR; Scheff RJ; Thomas SS; Guarino MJ; Masters GA; Kalinsky K; Gandhi L; Bardia A; Messersmith WA
• Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
  Breast Cancer Res Treat Volume: 156 Page(s): 453 - 464
  04/01/2016 Authors: Greenlee H; Crew KD; Capodice J; Awad D; Buono D; Shi Z; Jeffres A; Wyse S; Whitman W; Trivedi MS
• Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
  Volume: 76
  02/15/2016 Authors: Goetz MP; Beeram M; Beck T; Conlin AK; Dees EC; Dickler MN; Helsten TL; Conkling PR; Edenfield WJ; Richards DA
• Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
  Volume: 76
  02/15/2016 Authors: Bardia A; Diamond JR; Mayer IA; Starodub AN; Moroose RL; Isakoff SJ; Ocean AJ; Guarino MJ; Berlin JD; Messersmith WA
• Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
  Volume: 76
  02/15/2016 Authors: Kalinsky K; Chi D-C; Lee S; Bhardwaj A; Makower D; Cigler T; Crew KD; Hershman DL; Califano A; Silva J
• Inhibition of the autocrine IL6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+breast cancers
  Volume: 76
  02/15/2016 Authors: Silva J; Rodriguez-Barrueco R; Yu J; Kalinsky K; Maurer M; Califano A
• Identification of serum biomarkers associated with Akt inhibitor MK-2206-induced toxicity in a pre-surgical breast cancer (BC) trial
  Volume: 76
  02/15/2016 Authors: Mundi PS; Chen E; Sparano J; Andreopoulou E; Taback B; Wiechmann L; Feldman S; Ananthakrishnan P; Hibshoosh H; Connolly E
• Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
  NPJ Breast Cancer Volume: 2 Page(s): 16037
  01/01/2016 Authors: Adelson K; Ramaswamy B; Sparano JA; Christos PJ; Wright JJ; Raptis G; Han G; Villalona-Calero M; Ma CX; Hershman D
• Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study.
  Clin Med Insights Oncol Volume: 10 Page(s): 83 - 94
  01/01/2016 Authors: Consul N; Guo X; Coker C; Lopez-Pintado S; Hibshoosh H; Zhao B; Kalinsky K; Acharyya S
• Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.
  Genes Dev Volume: 29 Page(s): 1631 - 1648
  08/01/2015 Authors: Rodriguez-Barrueco R; Yu J; Saucedo-Cuevas LP; Olivan M; Llobet-Navas D; Putcha P; Castro V; Murga-Penas EM; Collazo-Lorduy A; Castillo-Martin M
• Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
  Clin Transl Oncol Volume: 17 Page(s): 539 - 546
  07/01/2015 Authors: Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
• Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology
  Volume: 33
  05/20/2015 Authors: Trivedi MS; Chen EI; Awad D; Koller A; Patel P; Kalinsky K; Maurer MA; Crew KD; Hershman DL
• Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.
  Volume: 33
  05/20/2015 Authors: Awad D; Greenlee H; Crew KD; Buono D; Capodice J; Kalinsky K; Maurer MA; Hershman DL
• Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors.
  J Acad Nutr Diet Volume: 115 Page(s): S42 - S56.e3
  05/01/2015 Authors: Greenlee H; Gaffney AO; Aycinena AC; Koch P; Contento I; Karmally W; Richardson JM; Lim E; Tsai W-Y; Crew K
• Master regulator (MR)-directed therapy in residual breast cancer patient derived xenografts (PDXs)
  Volume: 75
  05/01/2015 Authors: Kalinsky K; Mundi P; Hershman DL; Connolly E; Crew KD; Hibshoosh H; Calfiano A; Maurer M
• Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial
  Volume: 75
  05/01/2015 Authors: Adelson KB; Ramaswamy B; Sparano JA; Christos PJ; Wright JJ; Raptis G; Villalona MC; Ma CX; Hershman D; Baar J
• Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
  Volume: 75
  05/01/2015 Authors: Kalinsky K; Chi D-C; Lee S; Tiersten A; Makower D; Chuang E; Crew KD; Hershman DL; Silva J; Califano A
• Early optical tomography changes correlate with residual cancer burden scores in women receiving neoadjuvant chemotherapy
  Volume: 75
  05/01/2015 Authors: Lim EA; Gunther JE; Flexman M; Kim HK; Hibshoosh H; Kalinsky K; Crew K; Maurer M; Feldman S; Taback B
• Baseline joint pain predicts severity of subsequent joint symptoms in women initiating aromatase inhibitors for early stage breast cancer
  Volume: 75
  05/01/2015 Authors: Baer L; Crew KD; Awad D; Kalinsky K; Maurer M; Hershman DL
• Discordance in cyclin D1 changes after metformin exposure by different protein expression methods: Results from a "Window of Opportunity" trial
  Volume: 75
  05/01/2015 Authors: Kalinsky K; Hibshoosh H; Zheng T; Crew KD; Refice S; Feldman S; Taback B; Connolly E; Maurer M; Hershman DL
• Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors.
  J Acad Nutr Diet Volume: 115 Page(s): 709 - 723.e3
  05/01/2015 Authors: Greenlee H; Gaffney AO; Aycinena AC; Koch P; Contento I; Karmally W; Richardson JM; Lim E; Tsai W-Y; Crew K
• Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.
  Int J Food Sci Nutr Diet Volume: 2015 Page(s): 1 - 16
  01/01/2015 Authors: Crew KD; Xiao T; Thomas PS; Terry MB; Maurer M; Kalinsky K; Feldman S; Brafman L; Refice SR; Hershman DL
• Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.
  PLoS One Volume: 10 Page(s): e0145816
  01/01/2015 Authors: Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL
• Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.
  Springerplus Volume: 4 Page(s): 386
  01/01/2015 Authors: Zhang C; Wang S; Israel HP; Yan SX; Horowitz DP; Crockford S; Gidea-Addeo D; Clifford Chao KS; Kalinsky K; Connolly EP
• Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
  Breast J Volume: 21 Page(s): 377 - 386
  01/01/2015 Authors: Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R
• Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.
  Cancer Invest Volume: 32 Page(s): 439 - 444
  11/01/2014 Authors: Kalinsky K; Lim EA; Andreopoulou E; Desai AM; Jin Z; Tu Y; Hibshoosh H; Wang A; Greenlee H; Crew KD
• A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
  Breast Cancer Res Treat Volume: 146 Page(s): 145 - 152
  07/01/2014 Authors: Tu Y; Hershman DL; Bhalla K; Fiskus W; Pellegrino CM; Andreopoulou E; Makower D; Kalinsky K; Fehn K; Fineberg S
• Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
  Volume: 32
  05/20/2014 Authors: Tu Y; Hershman DL; Pellegrino CM; Andreopoulou E; Makower D; Fineberg S; Bhalla KN; Kalinsky K; Fehn K; Huang M
• Correlation between risk benefit index and uptake of breast cancer chemoprevention.
  Volume: 32
  05/20/2014 Authors: Sivasubramanian PS; Crew KD; Kalinsky K; Hershman DL; Maurer MA; Greenlee H; Reimers LL; Terry MB
• Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
  Volume: 32
  05/20/2014 Authors: Kalinsky K; Sparano JA; Andreopoulou E; Taback B; Wlechmann LS; Feldman SM; Ananthakrishnan P; Hibshoosh H; Manavaian J; Crew KD
• Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer
  Volume: 32
  05/20/2014 Authors: Kalinsky K; Chi D-C; Lee SM; Adelson KB; Crew KD; Chuang E; Makower D; Hershman DL; Califano A; Silva J
• Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
  Cancer Invest Volume: 32 Page(s): 150 - 157
  05/01/2014 Authors: Kalinsky K; Crew KD; Refice S; Xiao T; Wang A; Feldman SM; Taback B; Ahmad A; Cremers S; Hibshoosh H
• Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients.
  Clin Sarcoma Res Volume: 4 Page(s): 15
  01/01/2014 Authors: Baer LN; Savage DG; Hibshoosh HH; Kalinsky K
• Pre-surgical "window of opportunity" trial of metformin and atorvastatin in newly diagnosed operable breast cancer
  Volume: 73
  12/15/2013 Authors: Kalinsky K; Baer L; Tsai WY; Ngan MC; Feldman SM; Taback B; Ananthakrishnan P; Chen-Seetoo M; Hibshoosh H; Crew KD
• Phase I/11 trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
  Volume: 73
  12/15/2013 Authors: Kalinsky K; Chi D-C; Lee S; Adelson K; Andreopoulou E; Crew KD; Vahdat L; Sparano JA; Hershman DL; Califano A
• Influence of a clinic-based survivorship intervention on dietary change and lifestyle recommendations among Hispanic and non-Hispanic women following adjuvant therapy for breast cancer
  Volume: 73
  12/15/2013 Authors: Greenlee H; Awad D; Crew KD; Kalinsky K; Maurer M; Brafman L; Jayasena R; YTsai W; Neugut AL; Hershman DL
• Two-week change in optical tomography predicts residual cancer burden score in women treated with neoadjuvant chemotherapy
  Volume: 73
  12/15/2013 Authors: Lim EA; Gunther JE; Flexman M; Kim HK; Hibshoosh H; Kalinsky K; Crew K; Maurer M; Taback B; Feldman S
• Proteomic modulation in breast tumors after metformin use: Results from a "window of opportunity" trial
  Volume: 73
  12/15/2013 Authors: Kalinsky K; Zheng T; Crew KD; Refice S; Feldman SM; Taback B; Hibshoosh H; Su T; Maurer MM; Hershman DL
• Phase I study of erlotinib and metformin in triple negative breast cancer
  Volume: 73
  12/15/2013 Authors: Maurer M; Kalinsky K; Forman J; Jayasena R; Crew K; Hershman D
• Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ
  Volume: 73
  12/15/2013 Authors: Sivasubramanian PS; Reimers LL; Greenlee H; Terry MB; Hershman D; Maurer M; Kalinsky K; Awad D; Xiao T; Sandoval R
• Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography.
  J Biomed Opt Volume: 18 Page(s): 096012
  09/01/2013 Authors: Flexman ML; Kim HK; Gunther JE; Lim EA; Alvarez MC; Desperito E; Kalinsky K; Hershman DL; Hielscher AH
• Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
  J Comp Eff Res Volume: 2 Page(s): 393 - 403
  07/01/2013 Authors: Kalinsky K; Hershman DL
• Phase I trial of combined temsirolimus, erlotinib, and cisplatin in advanced solid tumors.
  Volume: 73
  04/15/2013 Authors: Maurer MA; Kalinsky K; Crew K; Jayasena R; Forman J; Lau Y-K; Parsons R; Hershman D
• Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors.
  Breast Cancer Res Treat Volume: 138 Page(s): 795 - 806
  04/01/2013 Authors: Hershman DL; Greenlee H; Awad D; Kalinsky K; Maurer M; Kranwinkel G; Brafman L; Jayasena R; Tsai W-Y; Neugut AI
• Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.
  Support Care Cancer Volume: 21 Page(s): 1077 - 1087
  04/01/2013 Authors: Greenlee H; Crew KD; Shao T; Kranwinkel G; Kalinsky K; Maurer M; Brafman L; Insel B; Tsai WY; Hershman DL
• Early Optical Tomography Changes Predict Breast Cancer Response to Neoadjuvant Chemotherapy
  Volume: 72
  12/15/2012 Authors: Lim EA; Gunther JE; Flexman M; Kim HK; Hibshoosh H; Kalinsky K; Crew K; Maurer M; Taback B; Feldman S
• PIK3CA mutations associate with decreased Ki67 in early stage breast cancer (BC) and better outcomes in patients even among those with low Ki67 tumors.
  Volume: 72
  12/15/2012 Authors: Datko FM; Patil S; Kalinsky K; Asher M; Wen YH; Hedvat C; Moynahan ME
• Immunocytochemistry staining for estrogen and progesterone receptor in circulating tumor cells: Concordance between primary and metastatic tumors.
  Volume: 72
  12/15/2012 Authors: Bischoff FZ; Pham T; Wong KL; Villarin E; Xu X; Kalinsky K; Mayer JA
• Randomized, single blind trial comparing limited and intensive survivorship interventions following adjuvant therapy in a multiethnic cohort of breast cancer survivors
  Volume: 72
  12/15/2012 Authors: Hershman DL; Greenlee H; Awad D; Kalinsky K; Maurer M; Kranwinkel G; Brooks-Brafman L; Fuentes D; Tsai W-Y; Crew KD
• Prospective Evaluation of Joint Symptoms in Postmenopausal Women Initiating Aromatase Inhibitors for Early Stage Breast Cancer
  Volume: 72
  12/15/2012 Authors: Crew KD; Chehayeb MD; Awad D; Kalinsky K; Maurer M; Kranwinkel G; Brafman L; Fuentes D; Hershman DL
• Pre-surgical Trial of Metformin in Overweight and Obese, Multiethnic Patients with Newly Diagnosed Breast Cancer
  Volume: 72
  12/15/2012 Authors: Kalinsky K; Crew KD; Refice S; Wang A; Feldman SM; Taback B; Hibshoosh H; Maurer M; Hershman DL
• Effects of high dose of bisphosphonate therapy on bone microarchitecture of the peripheral skeleton in women with early stage breast cancer
  Volume: 72
  12/15/2012 Authors: Shao T; Shane ES; McMahon D; Crew KD; Kalinsky K; Maurer M; Brown M; Gralow JR; Hershman DL
• Evaluation of the prognostic significance of androgen receptor (AR) expression in relation to ER expression in breast cancer (BC)
  Volume: 72
  12/15/2012 Authors: Gucalp A; Datko FM; Patil S; Hedvat CV; Kalinsky K; Hudis CA; Traina TA; Moynahan ME
• Pilot study of a 1-year intervention of high-dose vitamin D in women at high risk for breast cancer.
  Volume: 72
  12/15/2012 Authors: Sivasubramanian PS; Hershman DL; Maurer M; Kalinsky K; Feldman S; Brafman L; Ice SR; Kranwinkle G; Crew KD
• Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer.
  Breast Cancer Res Treat Volume: 136 Page(s): 535 - 545
  11/01/2012 Authors: Hershman DL; Richards CA; Kalinsky K; Wilde ET; Lu YS; Ascherman JA; Neugut AI; Wright JD
• Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
  J Oncol Pract Volume: 8 Page(s): e100 - e104
  09/01/2012 Authors: Clarke Hillyer G; Neugut AI; Crew KD; Kalinsky K; Maurer MA; Rotsides DZ; Danaceau J; Hershman DL
• Cracking open window of opportunity trials.
  J Clin Oncol Volume: 30 Page(s): 2573 - 2575
  07/20/2012 Authors: Kalinsky K; Hershman DL
• Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing
  Volume: 30
  05/20/2012 Authors: Xu X; Shen Y; Dewitt W; Pandya D; Bischoff FZ; Crew KD; Hershman DL; Maurer MA; Parsons R; Kalinsky K
• A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607)
  Volume: 30
  05/20/2012 Authors: Kalinsky K; Lee SJ; Lawrence DP; Iafrate AJ; Borger DR; Averbook BJ; Tarhini AA; Kirkwood JM
• Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy
  Volume: 30
  05/20/2012 Authors: Bischoff FZ; Pircher TJ; Pham T; Wong K; Villarin E; Kalinsky K; Mayer JA
• Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.
  J Clin Oncol Volume: 30 Page(s): 806 - 812
  03/10/2012 Authors: Hershman DL; Wilde ET; Wright JD; Buono DL; Kalinsky K; Malin JL; Neugut AI
• Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Low-Dose Metronomic Cyclophosphamide Alone or in Combination with Veliparib (ABT-888) in Chemotherapy-Resistant ER and/or PR-Positive, HER2/neu-Negative Metastatic Breast Cancer: New York Cancer Consortium Trial P8853.
  Volume: 71
  12/15/2011 Authors: Andreopoulou E; Chen AP; Zujewski JA; Kalinsky K; Vahdat L; Raptis G; Hershman D; Novic Y; Muggia F; Sparano J
• Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740.
  Volume: 71
  12/15/2011 Authors: Kalinsky K; Sparano JA; Kim M; Crew KD; Maurer MA; Taback B; Feldman SM; Hibshoosh H; Wiechmann LS; Adelson KB
• Uptake and Economic Impact of First-Cycle Colony Stimulating Factor Use during the Adjuvant Treatment of Breast Cancer.
  Volume: 71
  12/15/2011 Authors: Hershman DL; Wilde ET; Wright JD; Buono DL; Kalinsky K; Malin J; Tsai WY; Neugut AL
• Influence of Hospital Factors, Physician Factors and Type of Health Insurance on Receipt of Immediate Postmastectomy Reconstruction in Young Women with Breast Cancer
  Volume: 71
  12/15/2011 Authors: Hershman DL; Neugut AI; Richards CA; Kalinsky K; Charles AS; Wright JD
• Comparison of Biologic Differences in Tumors in a Matched Cohort of Hispanic and Caucasian Women with Early-Stage Breast Cancer Using the 21-Gene Recurrence Score Assay.
  Volume: 71
  12/15/2011 Authors: Lim EA; Hershman DL; Greenlee H; Crew KD; Maurer MA; Hibshoosh H; Kalinsky K
• Phase One Trial of Combined Temsirolimus, Erlotinib, and Cisplatin in Advanced Solid Tumors.
  Volume: 71
  12/15/2011 Authors: Maurer M; Kalinsky K; Crew K; Jayasena R; Forman J; Lau Y-K; Shaw J; Parsons R; Hershman D
• Uptake of Selective Estrogen Receptor Modulators and Other Breast Cancer Prevention Strategies among High-Risk Women Seen in a Breast Center.
  Volume: 71
  12/15/2011 Authors: Reimers LL; Campbell J; Hershman D; Greenlee H; Terry MB; Maurer M; Kalinsky K; Jayasena R; Sandoyal R; Alyarez M
• PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
  Breast Cancer Res Treat Volume: 129 Page(s): 635 - 643
  09/01/2011 Authors: Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
• Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.
  Volume: 29
  05/20/2011 Authors: Andreopoulou E; Chen AP; Zujewski J; Kim M; Hershman DL; Kalinsky K; Cigler T; Vahdat LT; Raptis G; Ramaswamy B
• Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
  Volume: 29
  05/20/2011 Authors: Kalinsky K; Sparano JA; Kim M; Crew KD; Maurer MA; Taback B; Feldman SM; Hibshoosh H; Wiechmann L; Adelson KB
• Safety of High-Dose Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer
  Volume: 70
  12/15/2010 Authors: Refice SF; Hershman DL; Maurer MA; Kalinsky K; Feldman S; Brafman L; Crew KD
• Improving Patient Accrual to "Window of Opportunity" Trials
  Volume: 70
  12/15/2010 Authors: Kalinsky K; Crew KD; Feldman SM; Taback B; Joseph K-AP; Hibshoosh H; Refice S; Maurer M; Hershman DL
• Phase II Study of Glucosamine with Chondroitin on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients
  Volume: 70
  12/15/2010 Authors: Greenlee H; Crew KD; Shao T; Kranwinkel G; Brafman L; Kalinsky K; Maurer M; Tsai WY; Hershman DL
• A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607)
  Volume: 28
  05/20/2010 Authors: Kalinsky K; Lee SJ; Lawrence DP; Kirkwood JM
• Mutant PIK3CA Is Detected in Both Pre-Invasive and Recurrent Breast Cancer
  Volume: 69 Page(s): 820S - 820S
  12/15/2009 Authors: Kalinsky K; Bhanot UK; Jacks LM; Hedvat CC; Patil S; Heguy A; Drobnjak M; Hudis C; Moynahan ME
• PIK3CA mutation associates with improved outcome in breast cancer.
  Clin Cancer Res Volume: 15 Page(s): 5049 - 5059
  08/15/2009 Authors: Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W
• The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
  Semin Oncol Volume: 34 Page(s): 546 - 554
  12/01/2007 Authors: Haluska F; Pemberton T; Ibrahim N; Kalinsky K
• Novel inhibitors in the treatment of metastatic melanoma.
  Expert Rev Anticancer Ther Volume: 7 Page(s): 715 - 724
  05/01/2007 Authors: Kalinsky K; Haluska FG